BioVie (BIVI) Stock: Buy, Sell, or Hold?
BIVI - BioVie, Inc. Common Stock
$1.93
0.02 (1.05%)
â˛
5d:
-4.93%
30d:
+23.72%
90d:
+16.27%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 21, 2026
0d
Get Alerted When BIVI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BIVI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BIVI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: BIVI is currently trading at $1.93, which is considered fair relative to its 30-day fair value range of $1.36 to $2.18.
Technical Outlook: Technically, BIVI is in a uptrend. The price is currently testing key support at $1.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BIVI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.25 (+172.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BIVI is in a uptrend. The price is currently testing key support at $1.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BIVI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.25 (+172.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.36 -
$2.18
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 172.3% below Wall St target ($5.25)
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.36 -
$2.18
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.89
Resistance Level
$2.49
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.06
Wall Street Target
$5.26
(+172.3%)
Share & Embed Analysis
Last updated: September 13, 2026 11:18 AM ET
Data refreshes hourly during market hours. Next update: 12:18 PM
Data refreshes hourly during market hours. Next update: 12:18 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIVI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$849 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$290 | 59 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
BUY
20 analysts |
$34 | 52 HOLD |
